Ying Du Sells 23,669 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 23,669 shares of the company's stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $36.13, for a total value of $855,160.97. Following the completion of the sale, the chief executive officer now owns 514,982 shares of the company's stock, valued at $18,606,299.66. This trade represents a 4.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ying Du also recently made the following trade(s):

• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $28.57, for a total value of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The stock was sold at an average price of $28.09, for a total value of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The shares were sold at an average price of $33.11, for a total transaction of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The stock was sold at an average price of $35.89, for a total transaction of $208,449.12.

Zai Lab Price Performance

Shares of ZLAB stock traded down $1.45 during midday trading on Friday, hitting $34.74. The company had a trading volume of 759,523 shares, compared to its average volume of 905,961. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -13.95 and a beta of 0.96. Zai Lab Limited Unsponsored ADR has a 52-week low of $16.01 and a 52-week high of $44.34. The company's 50 day simple moving average is $33.35 and its 200 day simple moving average is $31.02.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The business had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. Analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Hedge Funds Weigh In On Zai Lab

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in Zai Lab in the fourth quarter valued at $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab in the fourth quarter valued at about $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Zai Lab in the first quarter valued at about $75,000. Barclays PLC boosted its holdings in Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after buying an additional 2,856 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new position in Zai Lab during the first quarter worth about $110,000. Institutional investors and hedge funds own 41.65% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. JPMorgan Chase & Co. boosted their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Scotiabank began coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target on the stock. Finally, Bank of America reiterated a "neutral" rating and set a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.